CTX1 is a p53 activator that overcomes HdmX-mediated p53 inhibition; it exhibits potent anti-cancer activity in mouse models of acute myeloid leukemia (AML); it enhances survival in AML model systems when administered at 30 mg/kg (i.p., five days a week for 3 weeks); it shows significant anti-cancer activity both as a single agent and in combination with nutlin-3.